News

Article

Advanced Biosciences Laboratories, PATH Partner in Vaccine Production

Advanced Biosciences Laboratories will support the development and production of a novel Shigella vaccine candidate for PATH.

Advanced BioScience Laboratories, Inc. (ABL), a biomedical contract research and manufacturing organization, has been selected by PATH, an international nonprofit global health organization, to support the development and production of a novel Shigella vaccine candidate. ABL will develop a scalable GMP production process to produce toxicology and Phase I clinical supply at its facility located in Rockville, Maryland.

The vaccine candidate is based on IpaB/IpaD fusion protein technology developed in the laboratory of Wendy Picking, associate professor in the Department of Microbiology and Molecular Genetics at Oklahoma State University. The IpaB and IpaD proteins are highly conserved within Shigella species and, therefore, are expected to stimulate broad protective immune responses against multiple serotypes, according to ABL.

Source: ABL

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content